What increased confidence in Biogen's latest Alzheimer's drug means for Eli Lilly

What increased confidence in Biogen’s latest Alzheimer’s drug means for Eli Lilly

A pedestrian walks past the Biogen Inc. corporate headquarters in Cambridge, Massachusetts, Monday, June 7, 2021.

Adam Glanzman | Bloomberg | Getty Images

Wall Street has a growing belief that US drug regulators will approve Biogen’s latest experimental Alzheimer’s disease treatment (BIIB) after detailed late-stage clinical trial data is released. This is a development that may have positive implications for Eli Lily (LLY) because the Club holding company is studying a similar disease-targeting drug.

#increased #confidence #Biogens #latest #Alzheimers #drug #means #Eli #Lilly

Leave a Comment

Your email address will not be published. Required fields are marked *